•  Bone is a living, growing tissue made up of cells, vessels and crystals of calcium compounds.
•  Bone is remodeled throughout life. Remodeling is the process in which bones are broken down then built back up again through bone formation.
•  10% of skeletal bone gets replaced this way each year.

Osteoporosis comes from Greek name meaning porous bone. It occurs when there is an imbalance between bone breakdown and bone formation, causing the bone to become very weak and spongy, increasing its liability for break and fracture.

Composition:

Each Bon-One® tablet contains 0.25, 0.5 or 1.0 µg of alfacalcidol.

Indications:

• Improvement of various symptoms (hypocalcemia, tetany, bone pain, bone lesions, etc.) due to abnormal vitamin D metabolism in the following conditions:
  • Chronic renal failure
  • Hypoparathyroidism
  • Vitamin D resistant rickets and osteomalacia
• Osteoporosis

Dosage and Administration:

The dose should be adjusted with careful monitoring of the serum Ca level.

• Chronic renal failure and osteoporosis: For adults, 0.25 — 1.0 µg, as alfacalcidol, of Bon-One® tablet is generally administered orally once a day. The dose should be adjusted according to the age of the patients and the severity of symptoms.
• Hypoparathyroidism and other diseases associated with abnormal vitamin D metabolism: For adults, 1.0 — 4.0 µg, as alfacalcidol, of Bon-One® tablet is generally administered orally once a day. The dose should be adjusted according to the dieases, age of the patients, severity of symptoms, and the type of the diseases.

Dosage for children:

The general oral dose for children with osteoporosis ranges 0.01 —0.03 µg/ kg as alfacalcidol once a day, and that for the other indications ranges 0.05 — 0.1 µg/ kg as alfacalcidol once a day. The dose should be adjusted according to the diseases and the severity symptoms.